|
|
|
|
|
Calcidiol
drug data and news
Calcidiol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Calcidiol | ||
| Brand Names/Synonyms | Calcidiol; Calcifediol; Calcifediol Anhydrous; Calcifediolum [Inn-Latin]; Calcifidiol; Calderol; Delakmin | ||
| Indication | Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Calcidiol is a form of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. | ||
| Mechanism Of Action | Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. | ||
| Calcidiol News (When available) |
| ||
| Dosage Forms | CAPSULES | ||
| Drug_Category | ATC:A11CC06; Antihypocalcemic Agents; Antihypoparathyroid Agents; Vitamins (Vitamin D) | ||
| Absorption | Readily absorbed. | ||
| Interactions | [an error occurred while processing this directive]Toxicity | Bone pain; constipation (especially in children or adolescents); diarrhea; drowsiness; dryness of mouth; headache (continuing); increased thirst; increase in frequency of urination, especially at night, or in amount of urine; irregular heartbeat; itching skin; loss of appetite; metallic taste; muscle pain; nausea or vomiting (especially in children or adolescents); unusual tiredness or weakness. | |
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-[4-[2-(5-hydroxy-2-methylidene-cyclohexylidene)ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methyl-heptan-2-ol | ||
| Chemical Formula | C27H44O2 | ||
| Molecular Weight | 400.637 g/mol | ||
| Smiles String | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C | ||
| Melting Point | Not Available | ||
| Water Solubility | Insoluble | ||
| State | Solid | ||
| LogP/Hphobicity | 5.785 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D3. | ||
| Half Life | 288 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Calcifediol.html http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/vit_0265.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00428 | ||
| CAS Registry Number | 19356-17-3 | ||
| KEGG Compound ID | C01561 | ||
| PubChem ID | SID:171856 | ||
| PharmGKB ID | PA452501 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |